On September 22, 2020 AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, reported that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis (Press release, AXIM Biotechnologies, SEP 22, 2020, View Source;utm_medium=rss&utm_campaign=axim-biotechnologies-receives-notice-of-u-s-patent-allowance-for-proprietary-compounds-and-methods-targeting-tumor-metastasis-through-qsox1 [SID1234565474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earlier this year, Sapphire Biotech, a subsidiary of AXIM, announced that Skysong Innovations, LLC, the intellectual property management company for Arizona State University, exclusively licensed Patents, Technical Information and Materials (the "Technology") to Sapphire on behalf of ASU and the Mayo Clinic.

The licensed Technology includes SBI-183, which is covered by this patent. SBI-183 selectively targets QSOX1 and, in animal models, has been found to inhibit tumor growth, invasion and suppress metastasis of tumors by inactivating QSOX1.

"At our core, we are an oncology company dedicated to reducing metastasis in cancer patients around the world. This year, roughly 1.8 million people will be diagnosed with cancer in the U.S. alone and we hope to help as many of those people prolong their life as possible," said AXIM Biotech CEO John W. Huemoeller II. "This patent proves that the oncology research we are doing at AXIM is different from the approach others are taking and we are confident in our choice to do so."

Under this invention, AXIM intends to continue generating and testing analogs of SBI-183 to discover the most biologically active form of the compound. Currently, SPX-1009 has proven itself to be tenfold more potent in suppressing tumor invasion and metastasis in vitro than SBI-183. After further testing, SPX-1009 was shown to suppress invasion of breast, kidney and pancreas tumor cells in 2D and 3D invasion assays at tenfold lower concentrations than the parent compound SBI-183.

"I am enthusiastic about the future of analogs of our lead compound SBI-183. Since QSOX1 is a major player in metastasis, identification of QSOX1 inhibitors that suppress metastasis can be used in combination with other anti-neoplastic drugs to deliver a ‘one-two punch’ against cancer," said Dr. Douglas Lake, Ph.D. and co-founder of Sapphire Biotech.

On September 22, 2020 Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical trial and to introduce its new CEO, Joel Lewis (Press release, Galectin Therapeutics, SEP 22, 2020, View Source [SID1234565472]). The Investor Call is scheduled for Tuesday, September 29, 2020, at 4:00 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation can be accessed by dialing (844) 899-6544 and entering the conference ID: 3695038 or at the following webcast link: View Source A copy of the presentation to be used for the call can be found on the Company’s website at View Source

The call is expected to last one hour, including a Q&A session that will follow the formal remarks. The Company encourages the investment community to submit their questions in advance to: [email protected] and no later than Friday, September 25th at 4 PM EDT.

On September 22, 2020 GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE) technology reported it completed treatment of the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE Phase I/II clinical trial (Press release, GT Biopharma, SEP 22, 2020, View Source [SID1234565471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first patient treated with GTB-3550 at a 25mcg/kg/day dose showed a decrease in AML blast levels from 18% to 12% in the bone marrow. Additionally, we observed an increase in the patient’s NK cell activity and numbers attributable to the IL-15 component of the TriKE molecule with no appreciable increase of a hyper-active T-cell population which could have resulted in cytokine release syndrome (CRS) or other T-cell associated toxicities. The patient experienced no adverse reactions including no constitutional symptoms such as fever, tachycardia, or chills. We also observed improvement in marrow cellularity, a decrease in AML blast levels, and improving platelet and red blood cells numbers. The patient will be retreated with an additional round of GTB-3550 therapy at the 25mcg/kg/day dose.

The open-label, dose-escalation Phase I portion of the trial will evaluate GTB-3550 in patients with CD33-expressing, high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia (AML) or advanced systemic mastocytosis, and will determine safety and tolerability as well as the pharmacologically active dose and maximum tolerated dose of GTB-3550. The Phase II portion of the trial is planned to further evaluate the efficacy of GTB-3550 in this patient population.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased to see a reduction in AML blast levels at a dose of 25mcg/kg/day of GTB-3550." Mr. Cataldo further stated "we hope to see the continued absence of toxicity, and see additional signals of efficacy as we continue to dose escalate GTB-3550."

On September 22, 2020 Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) Application for GEN-011, an adoptive T cell therapy targeting neoantigens and designed to improve upon the limitations of TIL and TCR therapies (Press release, Genocea Biosciences, SEP 22, 2020, View Source [SID1234565470]). The IND allows Genocea to initiate a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy. The trial will evaluate safety, T cell proliferation and persistence as well as clinical activity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GEN-011 builds on the power of our ATLAS platform, as demonstrated in our GEN-009 clinical trial, to identify the relevant neoantigens which drive robust anti-tumor T cell responses in patients, regardless of HLA type," said Chip Clark, President and Chief Executive Officer of Genocea. "Using a patient’s peripheral T cells, already programmed to kill cancer cells with relevant neoantigens, enables this non-engineered therapy to rapidly scale. We therefore believe GEN-011 may eventually offer efficacy, accessibility and cost advantages to patients and providers."

Genocea plans to enroll up to 24 patients across several tumor types in the Phase 1/2 trial. In one cohort, patients will receive multiple low doses of GEN-011 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will receive a single GEN-011 dose after lymphodepletion and a high dose of IL-2.

On September 22, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope technology with release of the new RNA-Protein Co-Detection Assays (Press release, Bio-Techne, SEP 22, 2020, View Source [SID1234565469]). The RNAscope technology is an advanced in situ hybridization (ISH) assay that enables visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bio-Techne’s new Co-Detection Assays allow researchers to simultaneously examine cell-type specific gene expression and identify cellular sources of secreted proteins. Typical ISH and immunohistochemistry (IHC) are complementary techniques, bridging the gap between RNA and protein analysis. Yet, protocol optimizations, at a single cell level, may be quite challenging, especially at a risk of losing limited samples. The new workflow now enables a wider range of IHC-validated antibodies to be combined with RNA ISH at a greatly improved success rate, while saving costly optimization time and preserving precious samples.

"We are thrilled to extend our leadership in RNA in situ analysis into spatial multi-omics with the release of the RNA-Protein Co-Detection Assays," commented Kim Kelderman, President of Bio-Techne’s Diagnostics and Genomics Segment. "These new assays combine the strengths of our proprietary RNAscope core technology with our extensive antibody portfolio to provide new insights into cellular mechanisms."

The new assays utilize Bio-Techne’s patented RNAscope and BaseScope signal amplification and background suppression technologies to deliver supreme specificity and sensitivity with optimal signal-to-noise detection. Using RNA-Protein Co-Detection Assays, advanced scientific questions can be addressed, such as interactions of pathogens and host cell markers in infectious diseases and understanding complexities of splice variants and biomarker levels in cancer biology. In addition, the new assays enable researchers, utilizing antibodies in their studies, to correlate RNA-protein expression and evaluate antibody specificity.

"The new RNA-Protein Co-Detection Assays are an important advance for investigators studying the biological processes in single cells and within precious tissue samples," stated Dave Eansor, President of Bio-Techne’s Protein Sciences Segment. "At Bio-Techne, we are proud that our IHC expertise and high-quality R&D Systems and Novus Biologicals antibody offerings can be combined with the power of RNAscope and BaseScope detection."